Essex Bio-Technology 1061.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

2.02

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in HKD, from our data supplier.

FY2025

Revenue

HK$1.81bn

FY2016FY2025

Net income

HK$318.1m

FY2016FY2025

Free cash flow

HK$131.7m

FY2016FY2025

Shareholders' equity

HK$2.41bn

FY2016FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	HK$1.81bn	HK$1.67bn	HK$1.71bn	HK$1.32bn	HK$1.64bn	HK$978.1m	HK$1.28bn	HK$1.18bn	HK$899.6m	HK$775.7m
Gross profit	HK$1.62bn	HK$1.50bn	HK$1.54bn	HK$1.19bn	HK$1.40bn	HK$793.8m	HK$1.03bn	HK$973.5m	HK$737.6m	HK$623.0m
Research and development	HK$42.7m	HK$29.8m	HK$39.1m	HK$41.6m	HK$28.7m	HK$22.9m	HK$3.4m	HK$18.1m	HK$6.4m	HK$5.7m
Operating income	HK$367.8m	HK$320.7m	HK$310.3m	HK$273.0m	HK$403.1m	HK$213.8m	HK$346.7m	HK$264.2m	HK$206.5m	HK$171.9m
Net income	HK$318.1m	HK$307.2m	HK$275.3m	HK$225.4m	HK$346.0m	HK$218.9m	HK$302.5m	HK$231.1m	HK$167.3m	HK$136.3m
Diluted earnings per share	0.56	0.54	0.46	0.38	0.57	0.38	0.52	0.38	0.30	0.24

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total assets	HK$3.49bn	HK$2.98bn	HK$2.83bn	HK$2.71bn	HK$2.86bn	HK$2.42bn	HK$2.08bn	HK$1.45bn	HK$1.16bn	HK$933.3m
Cash and short-term investments	HK$784.1m	HK$560.7m	HK$515.0m	HK$543.5m	HK$671.4m	HK$599.8m	HK$483.9m	HK$311.1m	HK$240.6m	HK$156.2m
Total liabilities	HK$1.08bn	HK$859.3m	HK$903.8m	HK$981.0m	HK$1.13bn	HK$995.1m	HK$880.8m	HK$520.8m	HK$420.3m	HK$376.4m
Debt	HK$346.9m	HK$187.0m	HK$294.0m	HK$489.7m	HK$565.2m	HK$562.8m	HK$369.3m	HK$189.4m	HK$158.0m	HK$160.2m
Shareholders' equity	HK$2.41bn	HK$2.12bn	HK$1.92bn	HK$1.73bn	HK$1.73bn	HK$1.43bn	HK$1.20bn	HK$928.9m	HK$739.5m	HK$556.9m
Shares outstanding	567m	572m	594m	598m	602m	577m	578m	603m	564m	566m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from operations	HK$306.3m	HK$368.5m	HK$339.2m	HK$382.8m	HK$409.2m	HK$299.2m	HK$232.9m	HK$200.9m	HK$193.7m	HK$85.3m
Capital spending	−HK$174.6m	−HK$44.4m	−HK$128.0m	−HK$282.9m	−HK$244.5m	−HK$317.6m	−HK$165.8m	−HK$99.3m	−HK$66.5m	−HK$36.1m
Free cash flow	HK$131.7m	HK$324.1m	HK$211.2m	HK$99.9m	HK$164.6m	−HK$18.4m	HK$67.0m	HK$101.6m	HK$127.2m	HK$49.2m
Dividends paid	−HK$73.7m	−HK$59.6m	−HK$39.9m	−HK$54.5m	−HK$51.9m	−HK$28.9m	−HK$39.3m	−HK$31.4m	−HK$32.0m	−HK$14.0m

Latest quarters

By quarter end

	Jun 2026	Dec 2025	Jun 2025	Dec 2024	Jun 2024	Dec 2023	Jun 2023	Dec 2022
Revenue	HK$784.7m	HK$937.3m	HK$876.5m	HK$858.2m	HK$811.6m	HK$807.2m	HK$899.4m	HK$661.9m
Gross profit	HK$656.3m	HK$839.3m	HK$778.6m	HK$774.1m	HK$724.6m	HK$728.8m	HK$810.5m	HK$602.7m
Operating income	HK$132.9m	HK$184.6m	HK$183.2m	HK$164.2m	HK$156.5m	HK$127.9m	HK$188.5m	HK$128.0m
Net income	HK$110.7m	HK$154.7m	HK$163.4m	HK$149.8m	HK$157.4m	HK$105.4m	HK$169.8m	HK$86.2m
Diluted earnings per share	0.20	0.27	0.29	0.26	0.28	0.18	0.29	0.14
Cash from operations	HK$101.0m	HK$184.0m	HK$123.0m	HK$236.0m	HK$134.0m	HK$182.0m	HK$151.0m	HK$147.0m
Capital spending	−HK$27.0m	−HK$103.0m	−HK$70.0m	−HK$34.0m	−HK$9.0m	−HK$55.0m	−HK$73.0m	−HK$107.0m
Free cash flow	HK$74.0m	HK$81.0m	HK$53.0m	HK$202.0m	HK$125.0m	HK$127.0m	HK$78.0m	HK$40.0m
Total assets	HK$3.62bn	HK$3.49bn	HK$3.23bn	HK$2.98bn	HK$2.97bn	HK$2.83bn	HK$2.83bn	HK$2.71bn
Cash and short-term investments	HK$807.7m	HK$784.1m	HK$642.9m	HK$560.7m	HK$600.6m	HK$518.4m	HK$510.2m	HK$543.5m
Debt	HK$100.0m	HK$346.9m	HK$291.2m	HK$187.0m	HK$327.2m	HK$294.0m	HK$446.1m	HK$489.7m
Shareholders' equity	HK$2.55bn	HK$2.41bn	HK$2.27bn	HK$2.12bn	HK$2.02bn	HK$1.92bn	HK$1.81bn	HK$1.73bn

Financial ratios

Data as of 27 Oct 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	89.2%	89.8%	90.2%	90.3%	85.2%	81.2%
Operating margin	23.0%	21.2%	21.0%	20.6%	24.6%	25.8%
Net margin	17.5%	18.4%	16.1%	17.1%	21.1%	22.4%
Return on equity	13.2%	14.5%	14.3%	13.0%	19.9%	15.4%
Return on assets	9.1%	10.3%	9.7%	8.3%	12.1%	9.0%
Free cash flow yield	40.6%	34.6%	37.6%	53.3%	52.0%	51.2%
Revenue growth	8.6%	-2.2%	29.5%	-19.5%	67.4%	-23.6%
Earnings growth	3.5%	11.6%	22.1%	-34.8%	58.0%	-27.6%
Current ratio	2.11x	1.81x	1.54x	2.16x	2.24x	2.20x
Debt to equity	0.14x	0.08x	0.14x	0.28x	0.32x	0.39x
Equity ratio	69.1%	71.2%	68.0%	63.8%	60.6%	58.9%
Interest coverage	53.33x	58.28x	32.01x	23.71x	43.76x	177.48x
R&D as a share of sales	2.4%	1.8%	2.3%	3.2%	1.7%	2.3%
Buybacks as a share of market value	0.8%	3.7%	0.6%	0.7%	-4.3%	0.2%

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	11.2%	13.1%	10.7%
Operating income	10.5%	11.5%	10.7%
Net income	12.2%	7.8%	11.7%

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	89.5%	89.8%	88.1%	85.8%
Operating margin	19.8%	19.5%	20.7%	21.6%
Net margin	18.0%	17.3%	18.5%	18.9%

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Price to earnings	6.7	5.5	5.4	11.1	8.6	10.8	12.0	11.8	15.4	13.8
Price to sales	1.2	1.0	0.9	1.9	1.8	2.4	2.9	2.3	2.9	2.4

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 28 May 2026.

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Paid in the year	0.07	0.13	0.165	0.07	0.095	0.09	0.05	0.068

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Essex Bio-Technology 1061.HK · HKD

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology